Table 2.
Persistent ADL Disability by Type and Treatment Group
| Aspirin (N = 9525) | Placebo (N = 9589) | Total (N = 19 114) | |
|---|---|---|---|
| Persistent physical disability, participants N (%) | |||
| No persistent ADL disability | 9337 (98.0) | 9365 (97.7) | 18 702 (97.8) |
| Persistent ADL disabilitya | 166 (1.7) | 207 (2.2) | 373 (2.0) |
| Rate/1000 py | Rate/1000 py | HR (95% CI) | |
| Persistent ADL disability | 4.3 | 5.3 | 0.81 (0.66–1.00) |
| Concurrent persistent ADL disabilitya | |||
| Single ADL | 111 (66.9) | 165 (79.7) | 276 (74.0) |
| Two ADLs | 34 (20.5) | 25 (12.1) | 59 (15.8) |
| Three or more ADLs | 21 (12.7) | 17 (8.2) | 38 (10.2) |
| Total | 166 (100) | 207 (100) | 373 (100) |
| Persistent ADL disability by type; N (%)a | |||
| ADL 1 (walking across a room) | 42 (16.3) | 42 (14.7) | 84 (15.5) |
| ADL 2 (bathing) | 87 (33.9) | 100 (35.0) | 187 (34.4) |
| ADL 3 (dressing) | 66 (25.7) | 79 (27.6) | 145 (26.7) |
| ADL 4 (transferring from chair or bed) | 48 (18.7) | 47 (16.4) | 95 (17.5) |
| ADL 5 (toileting) | 12 (4.7) | 14 (4.9) | 26 (4.8) |
| ADL 6 (eating) | 2 (0.8) | 4 (1.4) | 6 (1.1) |
| Total | 257 (100) | 286 (100) | 543 (100) |
Notes: ADL disability is defined as “a lot of difficulty,” “unable to perform” or needing assistance with the ADL. Data apply to the first occasion of any ADL disability that was subsequently confirmed as persistent. ADL = Activities of daily living; CI = Confidence interval.
a N = number of participants with event; each participant could lose more than one ADL at the same time.